+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Colon Cancer (Oncology) - Drugs in Development, 2021

  • PDF Icon

    Report

  • 1498 Pages
  • December 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5521250
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Drugs In Development, 2021, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools, and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 30, 56, 1, 10, 238, 47 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 2, 43 and 12 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
Report Coverage
  • Colon Cancer - Overview
  • Colon Cancer - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Colon Cancer - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Colon Cancer - Companies Involved in Therapeutics Development
  • Colon Cancer - Drug Profiles
  • Colon Cancer - Dormant Projects
  • Colon Cancer - Discontinued Products
  • Colon Cancer - Product Development Milestones

Featured News & Press Releases
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact The Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Colon Cancer, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Colon Cancer - Dormant Projects, 2021
  • Colon Cancer - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Colon Cancer, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 1st Bio Therapeutics Inc
  • ABL Bio Inc
  • Abologix Sarl
  • Acomhal Research Inc
  • Actinium Pharmaceuticals Inc
  • Actym Therapeutics Inc
  • Advenchen Laboratories LLC
  • Adze Biotechnology Inc
  • Affimed GmbH
  • Agastiya Biotech LLC
  • AgomAb Therapeutics NV
  • AGV Discovery SAS
  • AIMM Therapeutics BV
  • Alligator Bioscience AB
  • Alphamab Oncology
  • Alpine Immune Sciences Inc
  • Alyra Therapeutics Inc
  • Amarin Corp Plc
  • Amgen Inc
  • Amrita Therapeutics
  • Anaeropharma Science Inc
  • ANP Technologies Inc
  • Antibody Therapeutics Inc
  • Aphios Corp
  • Apollomics Inc
  • AptaBio Therapeutics Inc
  • Arbele Ltd
  • Ardan Pharma
  • Ariz Precision Medicine Inc
  • Ascelia Pharma AB
  • Ascendis Pharma AS
  • Ascentawits Pharmaceuticals Ltd
  • Ashvattha Therapeutics LLC
  • AskAt Inc
  • AstraZeneca Plc
  • Asylia Therapeutics Inc
  • aTyr Pharma Inc
  • Aucentra Therapeutics Pty Ltd
  • Aurigene Discovery Technologies Ltd
  • Avican Inc
  • Avidin Biotechnology Ltd
  • Avidity Biosciences Inc
  • Azanta A/S
  • Bayer AG
  • Baylx Inc
  • BeiGene Ltd
  • Beijing Weiyuan Likang Biological Technology Co Ltd
  • BeyondSpring Inc
  • Binjiang Pharma, Inc.
  • BioAtla Inc
  • Biogazelle NV
  • BioMed Valley Discoveries Inc
  • Biomunex Pharmaceuticals
  • BioXpress Therapeutics SA
  • Black Diamond Therapeutics Inc
  • Bliss Biopharmaceutical (Hangzhou) Co Ltd
  • Blueprint Medicines Corp
  • Boehringer Ingelheim International GmbH
  • Bold Therapeutics Inc
  • BoYen Therapeutics Inc
  • Bristol-Myers Squibb Co
  • Calidi Biotherapeutics Inc
  • Can-Fite BioPharma Ltd
  • CanBas Co Ltd
  • Cancer Prevention Pharmaceuticals Inc
  • Cancure Ltd
  • Canget BioTekpharma LLC
  • Cantargia AB
  • Carina Biotech Pty Ltd
  • Celldex Therapeutics Inc
  • Cellective BioTherapy Inc
  • Celprogen Inc
  • Centrymed Pharmaceutical Inc
  • Changchun Huapu Biotechnology Co Ltd
  • ChemoCentryx Inc
  • Chengdu Huitai Biomedicine Co Ltd
  • Chengdu Jinrui Foundation Biotechnology Co Ltd
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd
  • Chinook Therapeutics Inc
  • Claradele Pharmaceuticals Inc
  • CMG Pharmaceutical Co Ltd
  • CNCure Biotech Inc
  • Codiak BioSciences Inc
  • Coherent Biopharma
  • CStone Pharmaceuticals Co Ltd
  • Cureport Inc
  • CV6 Therapeutics (Ni) Ltd
  • Cytodyn Inc
  • CytomX Therapeutics Inc
  • CZ BioMed Corp
  • DEKK-TEC Inc
  • Diazon Pharmaceuticals Inc
  • DiNonA Inc
  • Disulfican Ltd
  • Diverse Biotech Inc
  • Domainex Ltd
  • Dracen Pharmaceuticals Inc
  • Duet Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Elicera Therapeutics AB
  • Elixiron Immunotherapeutics Inc
  • Elucida Oncology Inc
  • Emcure Pharmaceuticals Ltd
  • Enara Bio Ltd
  • EncuraGen Co Ltd
  • Enochian Biosciences Inc
  • EntreChem SL
  • EnzymeBioSystems
  • Epigene Therapeutics Inc
  • Eucure (Beijing) Biopharma Co Ltd
  • Evestra Inc
  • F-star Therapeutics Inc
  • Faron Pharmaceuticals Oy
  • Felicitex Therapeutics Inc
  • For-Robin Inc
  • Frontbio Co Ltd
  • Fujifilm Holdings Corp
  • G1 Therapeutics Inc
  • GeneLeap Biotech
  • Genexine Inc
  • GeoVax Labs Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • GlycaNova AS
  • GlycoMimetics Inc
  • GlyTR Therapeutics Inc
  • GO Therapeutics Inc
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Guangzhou BeBetter Medicine Technology Co Ltd
  • HaimBio Ltd
  • Hamlet Pharma AB
  • Hangzhou Bensheng Pharmaceutical Co Ltd
  • HengRui YuanZheng Bio-Technology Co Ltd
  • Horizon Therapeutics Plc
  • Hummingbird Bioscience Pte Ltd
  • i2 Pharmaceuticals Inc
  • Ildong Pharmaceutical Co Ltd
  • ImCheck Therapeutics SAS
  • Immix BioPharma Inc
  • Immune Modulation Inc
  • ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
  • Immunicum AB
  • ImmunityBio Inc
  • Immunos Therapeutics AG
  • IMPACT Therapeutics Inc
  • Imugene Ltd
  • Infinity Pharmaceuticals Inc
  • Inmune Bio Inc
  • Innate Pharma SA
  • InnoCare Pharma Ltd
  • Innopharmax Inc
  • Intensity Therapeutics Inc
  • iOmx Therapeutics AG
  • iOnctura SA
  • Ix Therapeutics GmbH
  • J-Pharma Co Ltd
  • JenKem Technology Co Ltd
  • Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Jina Pharmaceuticals Inc
  • JN Biosciences LLC
  • Jubilant Therapeutics Inc
  • JW Pharmaceutical Corp
  • Kadmon Holdings Inc
  • KAHR medical Ltd
  • Kazia Therapeutics Ltd
  • Kineta Inc
  • Kintara Therapeutics Inc
  • Kringle Pharma Inc
  • Laekna Therapeutics Shanghai Co Ltd
  • LipoSeuticals Inc
  • Lixte Biotechnology Holdings Inc
  • Luzitin SA
  • MabVax Therapeutics Holdings Inc
  • Machavert Pharmaceuticals LLC
  • MacroGenics Inc
  • MaxiVAX SA
  • Medicon Pharmaceuticals Inc
  • MedPacto Inc
  • Merck & Co Inc
  • MicroQuin Ltd
  • Midissia Therapeutics Inc
  • Mito BioPharm LLC
  • Mosaic ImmunoEngineering Inc
  • Multimmune GmbH
  • MultiVir Inc
  • Nammi Therapeutics Inc
  • Nanjing Aimeifei Biomedical Technology Co Ltd
  • Nascent Biotech Inc
  • NED Biosystems Inc
  • Nektar Therapeutics
  • Nimbus Therapeutics LLC
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Novita Pharmaceuticals Inc
  • NutShell Biotech (Shanghai) Co Ltd
  • OBiO Technology (Shanghai) Corp Ltd
  • Oceanyx Pharmaceuticals Inc
  • Oita University Institute of Advanced Medicine Inc
  • Omeros Corp
  • Oncocross Co Ltd
  • Oncology Pharma Inc
  • Oncovir Inc
  • Oncoxx Biotech Srl
  • Oneness Biotech Co Ltd
  • Ono Pharmaceutical Co Ltd
  • Orano Med LLC
  • Orpheus Therapeutics Inc
  • Oryn Therapeutics
  • Pacylex Pharmaceuticals Inc
  • Panbela Therapeutics Inc
  • Parasol Biotech Co Ltd
  • Patrys Ltd
  • PAZ Pharma
  • Pfizer Inc
  • PharmAbcine Inc
  • Phenex Pharmaceuticals AG
  • Phio Pharmaceuticals Corp
  • Photolitec LLC
  • PHusis Therapeutics Inc
  • Pionyr Immunotherapeutics Inc
  • PNB Vesper Life Science Pvt Ltd
  • PolyPid Ltd
  • Primetime Life Sciences LLC
  • Prosetta Biosciences Inc
  • Protexase Therapeutics Inc
  • Provecs Medical GmbH
  • Provectus Biopharmaceuticals Inc
  • PsiOxus Therapeutics Ltd
  • PTC Therapeutics Inc
  • Pylum Biosciences Inc
  • Qilu Puget Sound Biotherapeutics Corp
  • Qu Biologics Inc
  • Ranger Biotechnologies AS
  • Riptide Bioscience Inc
  • Rubius Therapeutics Inc
  • Sagimet Biosciences
  • Sanofi
  • Sareum Holdings Plc
  • Savoy Pharmaceuticals Inc
  • Schrodinger Inc
  • SEEKYO Therapeutics
  • Senex Biotechnology
  • SetLance srl
  • Shanghai GeneChem Co Ltd
  • Shanghai Pharmaceutical Group Co Ltd
  • Shaperon Inc
  • Shattuck Labs Inc
  • Shenzhen Chipscreen Biosciences Co Ltd
  • Shionogi & Co Ltd
  • Sichuan Huiyang Life Science and Technology Corp
  • SideROS
  • SignalChem Lifesciences Corp
  • SignPath Pharma Inc
  • Simcere Pharmaceutical Group Ltd
  • SIRPant Immunotherapeutics Inc
  • Somantix BV
  • Soricimed Biopharma Inc
  • Sorrento Therapeutics Inc
  • Sotio AS
  • Sparx Therapeutics Inc
  • Sphaera Pharma Pte Ltd
  • Statera BioPharma Inc
  • Stcube Inc
  • Stingray Therapeutics LLC
  • Sumitomo Dainippon Pharma Co Ltd
  • Suzhou Sinovent Pharmaceuticals Co Ltd
  • Suzhou Stainwei Biotech Inc
  • Tactical Therapeutics Inc
  • TAE Life Sciences LLC
  • Takis Srl
  • Tango Therapeutics Inc
  • TargaGenix Inc
  • Tarus Therapeutics Inc
  • TenCure Ltd
  • TheraBioPhama
  • Theravectys SA
  • Tianjin Hengjia Biotechnology Development Co Ltd
  • Tiziana Life Sciences Plc
  • Toray Industries Inc
  • Totus Medicines Inc
  • Transcenta Holding Ltd
  • Transcode Therapeutics Inc
  • Transgene Biotek Ltd
  • TVAX Biomedical Inc
  • Twist Bioscience Corp
  • Tychon Bioscience Inc
  • Tyg Oncology Ltd
  • Tyme Inc
  • United Immunity Co Ltd
  • Vascular Biogenics Ltd
  • Vault Pharma Inc
  • Viomedix LLC
  • Viracta Therapeutics Inc
  • Virocure Inc
  • Virogin Biotech Ltd
  • WellMarker Bio Co Ltd
  • Westwood Bioscience Inc
  • WindMIL Therapeutics Inc
  • WntResearch AB
  • Wuhan Binhui Biotechnology Co Ltd
  • Wuhan YZY Biopharma Co Ltd
  • Wuxi Zhikang Hongyi Biological Technology Co Ltd
  • XOMA Corp
  • Y-mAbs Therapeutics Inc
  • Yuhan Corp
  • Zenith Epigenetics Ltd
  • ZIOPHARM Oncology Inc
  • Zovis Pharmaceuticals
  • Zymergen Inc